iBio, Inc. (NYSEAMERICAN:IBIO) Short Interest Update

iBio, Inc. (NYSEAMERICAN:IBIO) was the recipient of a large increase in short interest in the month of March. As of March 31st, there was short interest totalling 161,700 shares, an increase of 172.7% from the March 15th total of 59,300 shares. Approximately 1.9% of the company’s shares are sold short. Based on an average daily volume of 3,680,000 shares, the days-to-cover ratio is currently 0.0 days.

iBio Price Performance

Shares of iBio stock opened at $2.02 on Friday. The company has a current ratio of 0.91, a quick ratio of 0.91 and a debt-to-equity ratio of 0.04. iBio has a 1 year low of $1.02 and a 1 year high of $28.20.

iBio (NYSEAMERICAN:IBIO) last issued its quarterly earnings data on Friday, February 9th. The company reported ($2.42) EPS for the quarter.

Wall Street Analysts Forecast Growth

Separately, StockNews.com began coverage on shares of iBio in a research report on Wednesday, March 27th. They issued a “sell” rating on the stock.

About iBio

iBio, Inc, a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel.